The protective role of plant biophenols in mechanisms of Alzheimer's disease

Journal of Nutritional Biochemistry

Volumn 47, Issue , 2017, Pages 1-20

  Omar, Syed H ^a   Scott, Christopher J ^a   Hamlin, Adam S ^b   Obied, Hassan K ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Biophenols; Neurodegenerative disorders; Phytochemicals

Indexed keywords

ALKALOID; AMYLOID; AMYLOID PRECURSOR PROTEIN; ANTHOCYANIN; APIGENIN; BIOPHENOL DERIVATIVE; CAFFEIC ACID; CATECHIN; CHLOROGENIC ACID; CINNAMYL ALCOHOL; CURCUMIN; ELLAGIC ACID; FERULIC ACID; GALLIC ACID; GALLOCATECHIN; GINGEROL; ISORHAMNETIN; KAEMPFEROL; LUTEOLIN; MYRICETIN; OLEUROPEIN; POLYPHENOL DERIVATIVE; PROANTHOCYANIDIN; QUERCETIN; RESVERATROL; ROSIN; RUTOSIDE; SALIDROSIDE; TYROSOL; UNCLASSIFIED DRUG; ZINGERONE; ANTIOXIDANT; FLAVONOID; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PHENOL DERIVATIVE; PHYTOCHEMICAL; PLANT EXTRACT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BEHAVIOR; BIOASSAY; CELL LEVEL; COGNITION; DRUG MECHANISM; DRUG STRUCTURE; EPIGENETICS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; ANIMAL; BIOLOGICAL MODEL; DIETARY SUPPLEMENT; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; NERVE CELL; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BIOMEDICAL RESEARCH; DIETARY SUPPLEMENTS; FLAVONOIDS; HUMANS; MODELS, NEUROLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PHENOLS; PHYTOCHEMICALS; PLANT EXTRACTS; RESEARCH DESIGN; STILBENES;

EID: 85015012275     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.02.016     Document Type: Review

References (337)

1. [1] Rajawat, Y.S., Bossis, I., Autophagy in aging and in neurodegenerative disorders. Hormones 7 (2008), 46–61.
2. [2] Beckman, K.B., Ames, B.N., The free radical theory of aging matures. Physiol Rev 78 (1998), 547–581.
3. [3] Hagen, T.M., Oxidative stress, redox imbalance, and the aging process. Antioxid Redox Signal 5 (2003), 503–506.
4. [4] Villeponteau, B., Cockrell, R., Feng, J., Nutraceutical interventions may delay aging and the age-related diseases. Exp Gerontol 35 (2000), 1405–1417.
5. [5] Brown, R.C., Lockwood, A.H., Sonawane, B.R., Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113 (2005), 1250–1256.
6. [6] Gomez-Pinilla, F., Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9 (2008), 568–578.
7. [7] Francis, S.T., Head, K., Morris, P.G., Macdonald, I.A., The effect of flavanol-rich cocoa on the fMRI response to a cognitive task in healthy young people. J Cardiovasc Pharmacol 47:Suppl. 2 (2006), S215–S220.
8. [8] Obied, H.K., Biography of biophenols: past, present and future. Funct Foods Health Dis 3 (2013), 230–241.
9. [9] Obied, H.K., Prenzler, P.D., Omar, S.H., Ismael, R., Servili, M., Esposto, S., et al. Chapter six - pharmacology of olive biophenols. James, C.F., (eds.) Advances in molecular toxicology, 2012, Elsevier, 195–242.
10. [10] Schaffer, S., Asseburg, H., Kuntz, S., Muller, W.E., Eckert, G.P., Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria. Mol Neurobiol 46 (2012), 161–178.
11. [11] Singh, M., Arseneault, M., Sanderson, T., Murthy, V., Ramassamy, C., Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 56 (2008), 4855–4873.
12. [12] Choi, D.-Y., Lee, Y.-J., Hong, J.T., Lee, H.-J., Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res Bull 87 (2012), 144–153.
13. [13] Martin, C., Zhang, Y., Tonelli, C., Petroni, K., Plants, diet, and health. Annu Rev Plant Biol 64 (2013), 19–46.
14. [14] Camfield, D., Scholey, A., Pipingas, A., Silberstein, R., Kras, M., Nolidin, K., et al. Steady state visually evoked potential (SSVEP) topography changes associated with cocoa flavanol consumption. Physiol Behav 105 (2012), 948–957.
15. [15] Salomone, S., Caraci, F., Leggio, G.M., Fedotova, J., Drago, F., New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 73 (2012), 504–517.
16. [16] Maynard, S.D., Gelblum, J., Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease. Neuropsychiatr Dis Treat 9 (2013), 1629–1635.
17. [17] Dartigues, J.F., Feart, C., Risk factors for Alzheimer disease: aging beyond age?. Neurology 77 (2011), 206–207.
18. [18] Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992), 184–185.
19. [19] Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996), 99–102.
20. [20] Hock, B.J., Lattal, K.M., Kulnane, L.S., Abel, T., Lamb, B.T., Pathology associated memory deficits in Swedish mutant genome-based amyloid precursor protein transgenic mice. Curr Aging Sci 2 (2009), 205–213.
21. [21] Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000), 1571–1577.
22. [22] Kalimo, H., Lalowski, M., Bogdanovic, N., Philipson, O., Bird, T.D., Nochlin, D., et al. The Arctic AbetaPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated abeta. Acta Neuropathol Commun, 1, 2013, 60.
23. [23] Neve, R.L., McPhie, D.L., Chen, Y., Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein?. Biochem Soc Symp 67 (2001), 37–50.
24. [24] Hardy, J., Selkoe, D.J., Medicine - the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
25. [25] Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006), 352–357.
26. [26] Morris, G.P., Clark, I.A., Vissel, B., Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun, 2, 2014, 135.
27. [27] Herrup, K., The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18 (2015), 794–799.
28. [28] Crews, W.D., Harrison, D.W., Wright, J.W., A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: clinical findings from a sample of healthy, cognitively intact older adults. Am J Clin Nutr 87 (2008), 872–880.
29. [29] Rottkamp, C.A., Raina, A.K., Zhu, X., Gaier, E., Bush, A.I., Atwood, C.S., et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30 (2001), 447–450.
30. [30] Goekoop, R., Scheltens, P., Barkhof, F., Rombouts, S.A., Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation–a pharmacological fMRI study. Brain 129 (2006), 141–157.
31. [31] Bartus, R.T., On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163 (2000), 495–529.
32. [32] Hodges, J.R., Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain 129 (2006), 2811–2822.
33. [33] Mesulam, M., Guillozet, A., Shaw, P., Quinn, B., Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9 (2002), 88–93.
34. [34] Lane, R.M., Potkin, S.G., Enz, A., Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9 (2006), 101–124.
35. [35] Darvesh, S., Hopkins, D.A., Geula, C., Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4 (2003), 131–138.
36. [36] Loizzo, M.R., Tundis, R., Menichini, F., Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. Curr Med Chem 15 (2008), 1209–1228.
37. [37] Rollinger, J.M., Hornick, A., Langer, T., Stuppner, H., Prast, H., Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J Med Chem 47 (2004), 6248–6254.
38. [38] Lopez, O.L., Becker, J.T., Wisniewski, S., Saxton, J., Kaufer, D.I., DeKosky, S.T., Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002), 310–314.
39. [39] Ballard, C.G., Chalmers, K.A., Todd, C., McKeith, I.G., O'Brien, J.T., Wilcock, G., et al. Cholinesterase inhibitors reduce cortical abeta in dementia with Lewy bodies. Neurology 68 (2007), 1726–1729.
40. [40] Francis, P.T., Nordberg, A., Arnold, S.E., A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 26 (2005), 104–111.
41. [41] Nordberg, A., Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006), S12–S18.
42. [42] Navarro, A., Boveris, A., The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 292 (2007), C670–C686.
43. [43] Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26 (2006), 9057–9068.
44. [44] Gibson, G.E., Sheu, K.F., Blass, J.P., Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 105 (1998), 855–870.
45. [45] Parker, W.D. Jr., Filley, C.M., Parks, J.K., Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40 (1990), 1302–1303.
46. [46] Valla, J., Schneider, L., Niedzielko, T., Coon, K.D., Caselli, R., Sabbagh, M.N., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6 (2006), 323–330.
47. [47] Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J.W., et al. Mitochondrial abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19 (2005), 2040–2041.
48. [48] Eckert, A., Hauptmann, S., Scherping, I., Rhein, V., Muller-Spahn, F., Gotz, J., et al. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis 5 (2008), 157–159.
49. [49] Keil, U., Bonert, A., Marques, C.A., Scherping, I., Weyermann, J., Strosznajder, J.B., et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 279 (2004), 50310–50320.
50. [50] Swerdlow, R.H., Khan, S.M., A “mitochondrial cascade hypothesis” for sporadic Alzheimer's disease. Med Hypotheses 63 (2004), 8–20.
51. [51] Swerdlow, R.H., Kish, S.J., Mitochondria in Alzheimer's disease. Int Rev Neurobiol 53 (2002), 341–385.
52. [52] Moreira, P.I., Siedlak, S.L., Wang, X., Santos, M.S., Oliveira, C.R., Tabaton, M., et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol 66 (2007), 525–532.
53. [53] Moreira, P.I., Siedlak, S.L., Wang, X., Santos, M.S., Oliveira, C.R., Tabaton, M., et al. Increased autophagic degradation of mitochondria in Alzheimer disease. Autophagy 3 (2007), 614–615.
54. [54] Young, K.J., Bennett, J.P., The mitochondrial secret(ase) of Alzheimer's disease. J Alzheimers Dis 20:Suppl. 2 (2010), S381–S400.
55. [55] McCord, J.M., The evolution of free radicals and oxidative stress. Am J Med 108 (2000), 652–659.
56. [56] Pratico, D., Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29 (2008), 609–615.
57. [57] Pratico, D., Sung, S., Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 6 (2004), 171–175.
58. [58] Crapper, D.R., Krishnan, S.S., Dalton, A.J., Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science 180 (1973), 511–513.
59. [59] Yumoto, S., Kakimi, S., Ohsaki, A., Ishikawa, A., Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. J Inorg Biochem 103 (2009), 1579–1584.
60. [60] Ferreira, P.C., Piai Kde, A., Takayanagui, A.M., Segura-Munoz, S.I., Aluminum as a risk factor for Alzheimer's disease. Rev Lat Am Enfermagem 16 (2008), 151–157.
61. [61] Drago, D., Bettella, M., Bolognin, S., Cendron, L., Scancar, J., Milacic, R., et al. Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40 (2008), 731–746.
62. [62] Uemura, E., Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes. Exp Neurol 85 (1984), 10–18.
63. [63] Ribes, D., Torrente, M., Vicens, P., Colomina, M.T., Gomez, M., Domingo, J.L., Recognition memory and beta-amyloid plaques in adult Tg2576 mice are not modified after oral exposure to aluminum. Alzheimer Dis Assoc Disord 26 (2012), 179–185.
64. [64] Bush, A.I., Tanzi, R.E., Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5 (2008), 421–432.
65. [65] Budimir, A., Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm 61 (2011), 1–14.
66. [66] Myhrer, T., Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Neurosci Biobehav Rev 23 (1998), 131–139.
67. [67] Simpson, M.D., Royston, M.C., Deakin, J.F., Cross, A.J., Mann, D.M., Slater, P., Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains. Brain Res 462 (1988), 76–82.
68. [68] Thibault, O., Gant, J.C., Landfield, P.W., Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 6 (2007), 307–317.
69. [69] Prusiner, S.B., Novel proteinaceous infectious particles cause scrapie. Science 216 (1982), 136–144.
70. [70] Brundin, P., Melki, R., Kopito, R., Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11 (2010), 301–307.
71. [71] Soto, C., Estrada, L., Castilla, J., Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31 (2006), 150–155.
72. [72] Huang, L., Su, T., Li, X., Natural products as sources of new lead compounds for the treatment of Alzheimer's disease. Curr Top Med Chem 13 (2013), 1864–1878.
73. [73] Gauthier, S., Leuzy, A., Racine, E., Rosa-Neto, P., Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. Prog Neurobiol 110 (2013), 102–113.
74. [74] Houghton, P.J., Howes, M.J., Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 14 (2005), 6–22.
75. [75] Howes, M.J., Perry, N.S., Houghton, P.J., Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 17 (2003), 1–18.
76. [76] Dai, Q., Borenstein, A.R., Wu, Y., Jackson, J.C., Larson, E.B., Fruit and vegetable juices and Alzheimer's disease: the kame project. Am J Med 119 (2006), 751–759.
77. [77] Gu, Y., Scarmeas, N., Dietary patterns in Alzheimer's disease and cognitive aging. Curr Alzheimer Res, 8, 2011, 510.
78. [78] Ramassamy, C., Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545 (2006), 51–64.
79. [79] Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., et al. Grape-derived polyphenolics prevent abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28 (2008), 6388–6392.
80. [80] Sehgal, N., Gupta, A., Valli, R.K., Joshi, S.D., Mills, J.T., Hamel, E., et al. Withania Somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109 (2012), 3510–3515.
81. [81] Choudhary, M.I., Nawaz, S.A., ul-Haq, Z., Lodhi, M.A., Ghayur, M.N., Jalil, S., et al. Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys Res Commun 334 (2005), 276–287.
82. [82] Papandreou, M.A., Dimakopoulou, A., Linardaki, Z.I., Cordopatis, P., Klimis-Zacas, D., Margarity, M., et al. Effect of a polyphenol-rich wild blueberry extract on cognitive performance of mice, brain antioxidant markers and acetylcholinesterase activity. Behav Brain Res 198 (2009), 352–358.
83. [83] Malin, D.H., Lee, D.R., Goyarzu, P., Chang, Y.H., Ennis, L.J., Beckett, E., et al. Short-term blueberry-enriched diet prevents and reverses object recognition memory loss in aging rats. Nutrition 27 (2011), 338–342.
84. [84] Pase, M.P., Kean, J., Sarris, J., Neale, C., Scholey, A.B., Stough, C., The cognitive-enhancing effects of Bacopa Monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med 18 (2012), 647–652.
85. [85] van den Beukel, I., van Kleef, R.G., Oortgiesen, M., Differential effects of physostigmine and organophosphates on nicotinic receptors in neuronal cells of different species. Neurotoxicology 19 (1998), 777–787.
86. [86] Asthana, S., Greig, N.H., Hegedus, L., Holloway, H.H., Raffaele, K.C., Schapiro, M.B., et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 58 (1995), 299–309.
87. [87] Arendash, G.W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 17 (2009), 661–680.
88. [88] Cheng, B., Liu, X., Gong, H., Huang, L., Chen, H., Zhang, X., et al. Coffee components inhibit amyloid formation of human islet amyloid polypeptide in vitro: possible link between coffee consumption and diabetes mellitus. J Agric Food Chem 59 (2011), 13147–13155.
89. [89] Cioanca, O., Hritcu, L., Mihasan, M., Hancianu, M., Cognitive-enhancing and antioxidant activities of inhaled coriander volatile oil in amyloid beta(1-42) rat model of Alzheimer's disease. Physiol Behav 120 (2013), 193–202.
90. [90] Chauhan, N.B., Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J Ethnopharmacol 108 (2006), 385–394.
91. [91] Gupta, V.B., Indi, S.S., Rao, K.S., Garlic extract exhibits antiamyloidogenic activity on amyloid-beta fibrillogenesis: relevance to Alzheimer's disease. Phytother Res 23 (2009), 111–115.
92. [92] Lee, C., Park, G.H., Kim, C.Y., Jang, J.H., [6]-gingerol attenuates beta-amyloid-induced oxidative cell death via fortifying cellular antioxidant defense system. Food Chem Toxicol 49 (2011), 1261–1269.
93. [93] Omar, S.H., Ginkgolides and neuroprotective effects. Ramawat, K.G., Mérillon, J.-M., (eds.) Natural products, 2013, Springer, Berlin Heidelberg, 3697–3741.
94. [94] Nah, S.Y., Kim, D.H., Rhim, H., Ginsenosides: are any of them candidates for drugs acting on the central nervous system?. CNS Drug Rev 13 (2007), 381–404.
95. [95] Kim, E.J., Jung, I.H., Van Le, T.K., Jeong, J.J., Kim, N.J., Kim, D.H., Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. J Ethnopharmacol 146 (2013), 294–299.
96. [96] Chen, F., Eckman, E.A., Eckman, C.B., Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. FASEB J 20 (2006), 1269–1271.
97. [97] Elameen, A., Dragland, S., Klemsdal, S.S., Bioactive compounds produced by clones of Rhodiola Rosea maintained in the Norwegian germplasm collection. Pharmazie 65 (2010), 618–623.
98. [98] Qu, Z.Q., Zhou, Y., Zeng, Y.S., Li, Y., Chung, P., Pretreatment with Rhodiola Rosea extract reduces cognitive impairment induced by intracerebroventricular streptozotocin in rats: implication of anti-oxidative and neuroprotective effects. Biomed Environ Sci 22 (2009), 318–326.
99. [99] Li, Q.Y., Wang, H.M., Wang, Z.Q., Ma, J.F., Ding, J.Q., Chen, S.D., Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. Neurosci Lett 481 (2010), 154–158.
100. [100] Dhanasekaran, M., Holcomb, L.A., Hitt, A.R., Tharakan, B., Porter, J.W., Young, K.A., et al. Centella Asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. Phytother Res 23 (2009), 14–19.
101. [101] Liu, P., Kemper, L.J., Wang, J., Zahs, K.R., Ashe, K.H., Pasinetti, G.M., Grape seed polyphenolic extract specifically decreases abeta*56 in the brains of Tg2576 mice. J Alzheimers Dis 26 (2011), 657–666.
102. [102] Rezai-Zadeh, K., Arendash, G.W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214 (2008), 177–187.
103. [103] Biasibetti, R., Tramontina, A.C., Costa, A.P., Dutra, M.F., Quincozes-Santos, A., Nardin, P., et al. Green tea (−)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav Brain Res 236 (2013), 186–193.
104. [104] Akhondzadeh, S., Noroozian, M., Mohammadi, M., Ohadinia, S., Jamshidi, A.H., Khani, M., Melissa Officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry 74 (2003), 863–866.
105. [105] Iwasaki, K., Satoh-Nakagawa, T., Maruyama, M., Monma, Y., Nemoto, M., Tomita, N., et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan san for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66 (2005), 248–252.
106. [106] Szatmari, S.Z., Whitehouse, P.J., Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev, 2003, CD003119.
107. [107] Nyakas, C., Felszeghy, K., Szabo, R., Keijser, J.N., Luiten, P.G., Szombathelyi, Z., et al. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 15 (2009), 89–99.
108. [108] da Silva, A.L., Piato, A.L., Ferreira, J.G., Martins, B.S., Nunes, D.S., Elisabetsky, E., Promnesic effects of Ptychopetalum olacoides in aversive and non-aversive learning paradigms. J Ethnopharmacol 109 (2007), 449–457.
109. [109] Figueiro, M., Ilha, J., Linck, V.M., Herrmann, A.P., Nardin, P., Menezes, C.B., et al. The Amazonian herbal Marapuama attenuates cognitive impairment and neuroglial degeneration in a mouse Alzheimer model. Phytomedicine 18 (2011), 327–333.
110. [110] Eubanks, L.M., Rogers, C.J., Beuscher, AEt, Koob, G.F., Olson, A.J., Dickerson, T.J., et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 3 (2006), 773–777.
111. [111] Ma, X., Gang, D.R., In vitro production of huperzine a, a promising drug candidate for Alzheimer's disease. Phytochemistry 69 (2008), 2022–2028.
112. [112] Wang, R., Yan, H., Tang, X.C., Progress in studies of huperzine a, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27 (2006), 1–26.
113. [113] Bazoti, F.N., Bergquist, J., Markides, K.E., Tsarbopoulos, A., Noncovalent interaction between amyloid-beta-peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 17 (2006), 568–575.
114. [114] Grossi, C., Rigacci, S., Ambrosini, S., Ed Dami, T., Luccarini, I., Traini, C., et al. The polyphenol oleuropein aglycone protects TgCRND8 mice against ass plaque pathology. PLoS One, 8, 2013, e71702.
115. [115] Hartman, R.E., Shah, A., Fagan, A.M., Schwetye, K.E., Parsadanian, M., Schulman, R.N., et al. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis 24 (2006), 506–515.
116. [116] Kwak, H.M., Jeon, S.Y., Sohng, B.H., Kim, J.G., Lee, J.M., Lee, K.B., et al. Beta-secretase (BACE1) inhibitors from pomegranate (Punica Granatum) husk. Arch Pharm Res 28 (2005), 1328–1332.
117. [117] Orhan, I., Aslan, S., Kartal, M., Şener, B., Hüsnü Can Başer, K., Inhibitory effect of Turkish Rosmarinus Officinalis L. on acetylcholinesterase and butyrylcholinesterase enzymes. Food Chem 108 (2008), 663–668.
118. [118] Meng, P., Yoshida, H., Matsumiya, T., Imaizumi, T., Tanji, K., Xing, F., et al. Carnosic acid suppresses the production of amyloid-beta 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. Neurosci Res 75 (2013), 94–102.
119. [119] Yan, J.J., Cho, J.Y., Kim, H.S., Kim, K.L., Jung, J.S., Huh, S.O., et al. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133 (2001), 89–96.
120. [120] Akhondzadeh, S., Shafiee Sabet, M., Harirchian, M.H., Togha, M., Cheraghmakani, H., Razeghi, S., et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus Sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology (Berl) 207 (2010), 637–643.
121. [121] Papandreou, M.A., Kanakis, C.D., Polissiou, M.G., Efthimiopoulos, S., Cordopatis, P., Margarity, M., et al. Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus Sativus stigmas extract and its crocin constituents. J Agric Food Chem 54 (2006), 8762–8768.
122. [122] Perry, N.S., Bollen, C., Perry, E.K., Ballard, C., Salvia For dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 75 (2003), 651–659.
123. [123] Jia, H., Jiang, Y., Ruan, Y., Zhang, Y., Ma, X., Zhang, J., et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci Lett 367 (2004), 123–128.
124. [124] Park, C.H., Choi, S.H., Koo, J.W., Seo, J.H., Kim, H.S., Jeong, S.J., et al. Novel cognitive improving and neuroprotective activities of Polygala Tenuifolia Willdenow extract, BT-11. J Neurosci Res 70 (2002), 484–492.
125. [125] Heinrich, M., Lee, Teoh H., Galanthamine from snowdrop–the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 92 (2004), 147–162.
126. [126] Brenn, A., Grube, M., Jedlitschky, G., Fischer, A., Strohmeier, B., Eiden, M., et al. St. John's wort reduces Beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathol 24 (2014), 18–24.
127. [127] Dinamarca, M.C., Cerpa, W., Garrido, J., Hancke, J.L., Inestrosa, N.C., Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Mol Psychiatry 11 (2006), 1032–1048.
128. [128] Ringman, J.M., Frautschy, S.A., Cole, G.M., Masterman, D.L., Cummings, J.L., A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2 (2005), 131–136.
129. [129] Smith, M.A., Petot, G.J., Perry, G., Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J Alzheimers Dis 1 (1999), 203–206.
130. [130] Youdim, K.A., Dobbie, M.S., Kuhnle, G., Proteggente, A.R., Abbott, N.J., Rice-Evans, C., Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem 85 (2003), 180–192.
131. [131] Mamelak, M., Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging 28 (2007), 1340–1360.
132. [132] Sonnen, J.A., Breitner, J.C., Lovell, M.A., Markesbery, W.R., Quinn, J.F., Montine, T.J., Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med 45 (2008), 219–230.
133. [133] Reddy, P.H., Beal, M.F., Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14 (2008), 45–53.
134. [134] Tamagno, E., Guglielmotto, M., Monteleone, D., Tabaton, M., Amyloid-beta production: major link between oxidative stress and BACE1. Neurotox Res 22 (2012), 208–219.
135. [135] Tong, Y., Zhou, W., Fung, V., Christensen, M.A., Qing, H., Sun, X., et al. Oxidative stress potentiates BACE1 gene expression and abeta generation. J Neural Transm 112 (2005), 455–469.
136. [136] Butterfield, D.A., Reed, T., Newman, S.F., Sultana, R., Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43 (2007), 658–677.
137. [137] Butterfield, D.A., Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36 (2002), 1307–1313.
138. [138] Pereira, D.M., Valentão, P., Pereira, J.A., Andrade, P.B., Phenolics: from chemistry to biology. Molecules 14 (2009), 2202–2211.
139. [139] Alía, M., Mateos, R., Ramos, S., Lecumberri, E., Bravo, L., Goya, L., Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). Eur J Nutr 45 (2006), 19–28.
140. [140] Gao, Z., Xu, H., Huang, K., Effects of rutin supplementation on antioxidant status and iron, copper, and zinc contents in mouse liver and brain. Biol Trace Elem Res 88 (2002), 271–279.
141. [141] Wagner, C., Fachinetto, R., Dalla Corte, C.L., Brito, V.B., Severo, D., Dias, GdOC, et al. Quercitrin, a glycoside form of quercetin, prevents lipid peroxidation in vitro. Brain Res 1107 (2006), 192–198.
142. [142] Dairam, A., Fogel, R., Daya, S., Limson, J.L., Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J Agric Food Chem 56 (2008), 3350–3356.
143. [143] Avramovich-Tirosh, Y., Reznichenko, L., Mit, T., Zheng, H., Fridkin, M., Weinreb, O., et al. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4 (2007), 403–411.
144. [144] Robaszkiewicz, A., Balcerczyk, A., Bartosz, G., Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol Int 31 (2007), 1245–1250.
145. [145] Jimenez-Aliaga, K., Bermejo-Bescos, P., Benedi, J., Martin-Aragon, S., Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci 89 (2011), 939–945.
146. [146] Masella, R., Di Benedetto, R., Varì, R., Filesi, C., Giovannini, C., Novel mechanisms of natural antioxidant compounds in biological systems: involvement of glutathione and glutathione-related enzymes. J Nutr Biochem 16 (2005), 577–586.
147. [147] Butterfield, D.A., Lauderback, C.M., Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32 (2002), 1050–1060.
148. [148] Sultana, R., Perluigi, M., Butterfield, D.A., Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 8 (2006), 2021–2037.
149. [149] Markesbery, W.R., Lovell, M.A., Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64 (2007), 954–956.
150. [150] Gabbita, S.P., Lovell, M.A., Markesbery, W.R., Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71 (1998), 2034–2040.
151. [151] Lovell, M.A., Markesbery, W.R., Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 58 (2001), 392–396.
152. [152] Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 (2001), 759–767.
153. [153] Hoyer, S., Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105 (1998), 415–422.
154. [154] Hoyer, S., Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 35 (2000), 1363–1372.
155. [155] Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 91 (1994), 4766–4770.
156. [156] Mecocci, P., Polidori, M.C., Cherubini, A., Ingegni, T., Mattioli, P., Catani, M., et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59 (2002), 794–798.
157. [157] Rinaldi, P., Polidori, M.C., Metastasio, A., Mariani, E., Mattioli, P., Cherubini, A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24 (2003), 915–919.
158. [158] Dumont, M., Beal, M.F., Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 51 (2011), 1014–1026.
159. [159] Ilhan, A., Gurel, A., Armutcu, F., Kamisli, S., Iraz, M., Akyol, O., et al. Ginkgo Biloba prevents mobile phone-induced oxidative stress in rat brain. Clin Chim Acta 340 (2004), 153–162.
160. [160] Balu, M., Sangeetha, P., Murali, G., Panneerselvam, C., Age-related oxidative protein damages in central nervous system of rats: modulatory role of grape seed extract. Int J Dev Neurosci 23 (2005), 501–507.
161. [161] Mishra, S., Palanivelu, K., The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol, 11, 2008, 13.
162. [162] Banerjee, S., Mukherjee, P.K., Maulik, S., Garlic as an antioxidant: the good, the bad and the ugly. Phytother Res 17 (2003), 97–106.
163. [163] Frei, B., Higdon, J.V., Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133 (2003), 3275S–3284S.
164. [164] Lim, G.P., Chu, T., Yang, F., Beech, W., Frautschy, S.A., Cole, G.M., The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21 (2001), 8370–8377.
165. [165] Srividhya, R., Jyothilakshmi, V., Arulmathi, K., Senthilkumaran, V., Kalaiselvi, P., Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (−)-epigallocatechin-3-gallate. Int J Dev Neurosci 26 (2008), 217–223.
166. [166] Qiusheng, Z., Yuntao, Z., Rongliang, Z., Dean, G., Changling, L., Effects of verbascoside and luteolin on oxidative damage in brain of heroin treated mice. Pharmazie 60 (2005), 539–543.
167. [167] Javed, H., Khan, M., Ahmad, A., Vaibhav, K., Ahmad, M., Khan, A., et al. Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type. Neuroscience 210 (2012), 340–352.
168. [168] Luchsinger, J.A., Mayeux, R., Dietary factors and Alzheimer's disease. Lancet Neurol 3 (2004), 579–587.
169. [169] Tangney, C.C., Kwasny, M.J., Li, H., Wilson, R.S., Evans, D.A., Morris, M.C., Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 93 (2011), 601–607.
170. [170] Polidori, M.C., Mattioli, P., Aldred, S., Cecchetti, R., Stahl, W., Griffiths, H., et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 18 (2004), 265–270.
171. [171] Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6 (2010), 131–144.
172. [172] Mecocci, P., Polidori, M.C., Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 1822 (2012), 631–638.
173. [173] Pungcharoenkul, K., Thongnopnua, P., Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res 25 (2011), 1721–1726.
174. [174] Baum, L., Lam, C.W., Cheung, S.K., Kwok, T., Lui, V., Tsoh, J., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28 (2008), 110–113.
175. [175] Leenen, R., Roodenburg, A., Tijburg, L., Wiseman, S., A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur J Clin Nutr 54 (2000), 87–92.
176. [176] Young, J.F., Dragsted, L.O., Haraldsdottir, J., Daneshvar, B., Kall, M., Loft, S., et al. Green tea extract only affects markers of oxidative status postprandially: lasting antioxidant effect of flavonoid-free diet. Br J Nutr 87 (2002), 343–355.
177. [177] Wang, J.F., Schramm, D.D., Holt, R.R., Ensunsa, J.L., Fraga, C.G., Schmitz, H.H., et al. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. J Nutr 130 (2000), 2115S–2119S.
178. [178] Lambert, J.D., Elias, R.J., The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 501 (2010), 65–72.
179. [179] Calabrese, V., Cornelius, C., Trovato-Salinaro, A., Cambria, M.T., Locascio, M., Rienzo, L., et al. The hormetic role of dietary antioxidants in free radical-related diseases. Curr Pharm Des 16 (2010), 877–883.
180. [180] Serafini, M., Ghiselli, A., Ferro-Luzzi, A., In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr 50 (1996), 28–32.
181. [181] Darvesh, A.S., Carroll, R.T., Bishayee, A., Geldenhuys, W.J., Van der Schyf, C.J., Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. 2010.
182. [182] Gomez-Pinilla, F., Nguyen, T.T., Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr Neurosci 15 (2012), 127–133.
183. [183] Sellappan, S., Akoh, C.C., Krewer, G., Phenolic compounds and antioxidant capacity of Georgia-grown blueberries and blackberries. J Agric Food Chem 50 (2002), 2432–2438.
184. [184] Jain, K.K., The handbook of neuroprotection: Springer Science & Business Media. 2011.
185. [185] Lima, C.F., Valentao, P.C., Andrade, P.B., Seabra, R.M., Fernandes-Ferreira, M., Pereira-Wilson, C., Water and methanolic extracts of Salvia Officinalis protect HepG2 cells from t-BHP induced oxidative damage. Chem Biol Interact 167 (2007), 107–115.
186. [186] Ahlemeyer, B., Krieglstein, J., Neuroprotective effects of Ginkgo Biloba extract. Cell Mol Life Sci 60 (2003), 1779–1792.
187. [187] Bastianetto, S., Yao, Z.X., Papadopoulos, V., Quirion, R., Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity. Eur J Neurosci 23 (2006), 55–64.
188. [188] Narita, K., Hisamoto, M., Okuda, T., Takeda, S., Differential neuroprotective activity of two different grape seed extracts. PLoS One, 6, 2011, e14575.
189. [189] Zhu, Y., Bickford, P.C., Sanberg, P., Giunta, B., Tan, J., Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. Rejuvenation Res 11 (2008), 891–901.
190. [190] Dajas, F., Rivera-Megret, F., Blasina, F., Arredondo, F., Abin-Carriquiry, J., Costa, G., et al. Neuroprotection by flavonoids. Braz J Med Biol Res 36 (2003), 1613–1620.
191. [191] Tarozzi, A., Morroni, F., Hrelia, S., Angeloni, C., Marchesi, A., Cantelli-Forti, G., et al. Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-SY5Y cells. Neurosci Lett 424 (2007), 36–40.
192. [192] Dajas, F., Life or death: neuroprotective and anticancer effects of quercetin. J Ethnopharmacol 143 (2012), 383–396.
193. [193] Nehlig, A., The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol 75 (2013), 716–727.
194. [194] Duffy, K.B., Spangler, E.L., Devan, B.D., Guo, Z., Bowker, J.L., Janas, A.M., et al. A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats. Neurobiol Aging 29 (2008), 1680–1689.
195. [195] Wang, Y.J., Thomas, P., Zhong, J.H., Bi, F.F., Kosaraju, S., Pollard, A., et al. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 15 (2009), 3–14.
196. [196] Weinreb, O., Mandel, S., Amit, T., Youdim, M.B., Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15 (2004), 506–516.
197. [197] Rojanathammanee, L., Puig, K.L., Combs, C.K., Pomegranate polyphenols and extract inhibit nuclear factor of activated T-cell activity and microglial activation in vitro and in a transgenic mouse model of Alzheimer disease. J Nutr 143 (2013), 597–605.
198. [198] Uabundit, N., Wattanathorn, J., Mucimapura, S., Ingkaninan, K., Cognitive enhancement and neuroprotective effects of Bacopa Monnieri in Alzheimer's disease model. J Ethnopharmacol 127 (2010), 26–31.
199. [199] Omar, S.H., Cardioprotective and neuroprotective roles of oleuropein in olive. Saudi Pharm J 18 (2010), 111–121.
200. [200] Tasset, I., Pontes, A., Hinojosa, A., de la Torre, R., Túnez, I., Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model. Nutr Neurosci 14 (2011), 106–111.
201. [201] Zbarsky, V., Datla, K.P., Parkar, S., Rai, D.K., Aruoma, O.I., Dexter, D.T., Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 39 (2005), 1119–1125.
202. [202] Frozza, R.L., Bernardi, A., Hoppe, J.B., Meneghetti, A.B., Matté, A., Battastini, A.M., et al. Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol 47 (2013), 1066–1080.
203. [203] Haleagrahara, N., Siew, C.J., Mitra, N.K., Kumari, M., Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. Neurosci Lett 500 (2011), 139–143.
204. [204] Ugartondo, V., Mitjans, M., Lozano, C., Torres, J.L., Vinardell, M.P., Comparative study of the cytotoxicity induced by antioxidant epicatechin conjugates obtained from grape. J Agric Food Chem 54 (2006), 6945–6950.
205. [205] Matsuo, M., Sasaki, N., Saga, K., Kaneko, T., Cytotoxicity of flavonoids toward cultured normal human cells. Biol Pharm Bull 28 (2005), 253–259.
206. [206] Polydoro, M., De Souza, K., Andrades, M., Da Silva, E., Bonatto, F., Heydrich, J., et al. Antioxidant, a pro-oxidant and cytotoxic effects of Achyrocline satureioides extracts. Life Sci 74 (2004), 2815–2826.
207. [207] Khan, M.T., Orhan, I., Senol, F.S., Kartal, M., Sener, B., Dvorska, M., et al. Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. Chem Biol Interact 181 (2009), 383–389.
208. [208] Kaur, T., Pathak, C.M., Pandhi, P., Khanduja, K.L., Effects of green tea extract on learning, memory, behavior and acetylcholinesterase activity in young and old male rats. Brain Cogn 67 (2008), 25–30.
209. [209] Okello, E.J., Savelev, S.U., Perry, E.K., In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia Sinensis L. (tea) relevant to treatment of dementia. Phytother Res 18 (2004), 624–627.
210. [210] Ellman, G.L., Courtney, K.D., Andres, V., Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7 (1961), 88–95.
211. [211] Ljubenkov, I., Kri, A., Juki, M., Antioxidant and acetylcholinesterase inhibiting activity of several aqueous tea infusions in vitro. Food Technol Biotechnol 46 (2008), 368–375.
212. [212] Mukherjee, P.K., Kumar, V., Mal, M., Houghton, P.J., Acetylcholinesterase inhibitors from plants. Phytomedicine 14 (2007), 289–300.
213. [213] Roche, M., Dufour, C., Loonis, M., Reist, M., Carrupt, P.A., Dangles, O., Olive phenols efficiently inhibit the oxidation of serum albumin-bound linoleic acid and butyrylcholine esterase. Biochim Biophys Acta 2009 (1790), 240–248.
214. [214] Ahmed, T., Gilani, A.H., Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91 (2009), 554–559.
215. [215] Tu, S.H., Ku, C.Y., Ho, C.T., Chen, C.S., Huang, C.S., Lee, C.H., et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol Nutr Food Res 55 (2011), 455–466.
216. [216] Zhang, L., Cao, H., Wen, J., Xu, M., Green tea polyphenol (−)-epigallocatechin-3-gallate enhances the inhibitory effect of huperzine a on acetylcholinesterase by increasing the affinity with serum albumin. Nutr Neurosci 12 (2009), 142–148.
217. [217] Orhan, I., Kartal, M., Tosun, F., Sener, B., Screening of various phenolic acids and flavonoid derivatives for their anticholinesterase potential. Z Naturforsch C, 62, 2007, 829.
218. [218] Chung, J.H., Kim, M., Kim, H.K., Green tea polyphenols suppress nitric oxide–induced apoptosis and acetylcholinesterase activity in human neuroblastoma cells. Nutr Res 25 (2005), 477–483.
219. [219] Choi, G.N., Kim, J.H., Kwak, J.H., Jeong, C.-H., Jeong, H.R., Lee, U., et al. Effect of quercetin on learning and memory performance in ICR mice under neurotoxic trimethyltin exposure. Food Chem 132 (2012), 1019–1024.
220. [220] Ozarowski, M., Mikolajczak, P.L., Bogacz, A., Gryszczynska, A., Kujawska, M., Jodynis-Liebert, J., et al. Rosmarinus Officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia 91 (2013), 261–271.
221. [221] Xiao, J., Chen, X., Zhang, L., Talbot, S.G., Li, G.C., Xu, M., Investigation of the mechanism of enhanced effect of EGCG on huperzine A's inhibition of acetylcholinesterase activity in rats by a multispectroscopic method. J Agric Food Chem 56 (2008), 910–915.
222. [222] Tota, S., Awasthi, H., Kamat, P.K., Nath, C., Hanif, K., Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 209 (2010), 73–79.
223. [223] Katalinić, M., Rusak, G., Barović, J.D., Šinko, G., Jelić, D., Antolović, R., et al. Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. Eur J Med Chem 45 (2010), 186–192.
224. [224] Fan, P., Hay, A.-E., Marston, A., Hostettmann, K., Acetylcholinesterase-inhibitory activity of linarin from Buddleja davidii, structure-activity relationships of related flavonoids, and chemical investigation of Buddleja Nitida. Pharm Biol 46 (2008), 596–601.
225. [225] Wu, K.J., Hsieh, M.T., Wu, C.R., Wood, W.G., Chen, Y.F., Green tea extract ameliorates learning and memory deficits in ischemic rats via its active component polyphenol epigallocatechin-3-gallate by modulation of oxidative stress and neuroinflammation. Evid Based Complement Alternat Med, 2012, 2012, 163106.
226. [226] Albensi, B.C., Igoechi, C., Janigro, D., Ilkanich, E., Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?. Am J Alzheimers Dis Other Demen 19 (2004), 269–274.
227. [227] Wang, R., Li, Y.-B., Li, Y.-H., Xu, Y., Wu, H.-l., Li, X.-J., Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 1210 (2008), 84–91.
228. [228] Bae, J.H., Mun, K.C., Park, W.K., Lee, S.-R., Suh, S.-I., Baek, W.K., et al. EGCG attenuates AMPA-induced intracellular calcium increase in hippocampal neurons. Biochem Biophys Res Commun 290 (2002), 1506–1512.
229. [229] Chen, C.M., Lin, J.K., Liu, S.H., Lin-Shiau, S.Y., Novel regimen through combination of memantine and tea polyphenol for neuroprotection against brain excitotoxicity. J Neurosci Res 86 (2008), 2696–2704.
230. [230] Camilleri, A., Zarb, C., Caruana, M., Ostermeier, U., Ghio, S., Hogen, T., et al. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 2013 (1828), 2532–2543.
231. [231] Huang, H.C., Xu, K., Jiang, Z.F., Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta. J Alzheimers Dis 32 (2012), 981–996.
232. [232] Hao, J., Shen, W., Yu, G., Jia, H., Li, X., Feng, Z., et al. Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes. J Nutr Biochem 21 (2010), 634–644.
233. [233] Feng, Z., Bai, L., Yan, J., Li, Y., Shen, W., Wang, Y., et al. Mitochondrial dynamic remodeling in strenuous exercise-induced muscle and mitochondrial dysfunction: regulatory effects of hydroxytyrosol. Free Radic Biol Med 50 (2011), 1437–1446.
234. [234] Levenson, J.M., Sweatt, J.D., Epigenetic mechanisms in memory formation. Nat Rev Neurosci 6 (2005), 108–118.
235. [235] Levenson, J.M., O'Riordan, K.J., Brown, K.D., Trinh, M.A., Molfese, D.L., Sweatt, J.D., Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 279 (2004), 40545–40559.
236. [236] Guan, J.-S., Haggarty, S.J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459 (2009), 55–60.
237. [237] Pandey, M., Shukla, S., Gupta, S., Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer 126 (2010), 2520–2533.
238. [238] Nandakumar, V., Vaid, M., Katiyar, S.K., (−)-epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32 (2011), 537–544.
239. [239] Meja, K.K., Rajendrasozhan, S., Adenuga, D., Biswas, S.K., Sundar, I.K., Spooner, G., et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 39 (2008), 312–323.
240. [240] Lee, W.-J., Chen, Y.-R., Tseng, T.-H., Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep 25 (2011), 583–591.
241. [241] Rambold, A.S., Miesbauer, M., Olschewski, D., Seidel, R., Riemer, C., Smale, L., et al. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem 107 (2008), 218–229.
242. [242] Jeong, J.K., Moon, M.H., Bae, B.C., Lee, Y.J., Seol, J.W., Kang, H.S., et al. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci Res 73 (2012), 99–105.
243. [243] Bizat, N., Peyrin, J.M., Haik, S., Cochois, V., Beaudry, P., Laplanche, J.L., et al. Neuron dysfunction is induced by prion protein with an insertional mutation via a Fyn kinase and reversed by sirtuin activation in Caenorhabditis elegans. J Neurosci 30 (2010), 5394–5403.
244. [244] Caughey, B., Raymond, L.D., Raymond, G.J., Maxson, L., Silveira, J., Baron, G.S., Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 77 (2003), 5499–5502.
245. [245] Hafner-Bratkovic, I., Gaspersic, J., Smid, L.M., Bresjanac, M., Jerala, R., Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation. J Neurochem 104 (2008), 1553–1564.
246. [246] Serrano-Pozo, A., Frosch, M.P., Masliah, E., Hyman, B.T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med, 1, 2011, a006189.
247. [247] Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25 (2005), 8807–8814.
248. [248] Harvey, B.S., Musgrave, I.F., Ohlsson, K.S., Fransson, Å., Smid, S.D., The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro. Food Chem 129 (2011), 1729–1736.
249. [249] Choi, Y.T., Jung, C.H., Lee, S.R., Bae, J.H., Baek, W.K., Suh, M.H., et al. The green tea polyphenol (−)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 70 (2001), 603–614.
250. [250] Lee, J.W., Lee, Y.K., Ban, J.O., Ha, T.Y., Yun, Y.P., Han, S.B., et al. Green tea (−)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 139 (2009), 1987–1993.
251. [251] Zhao, L.N., Chiu, S.W., Benoit, J., Chew, L.Y., Mu, Y., The effect of curcumin on the stability of abeta dimers. J Phys Chem B 116 (2012), 7428–7435.
252. [252] Jeon, S.Y., Bae, K., Seong, Y.H., Song, K.S., Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 13 (2003), 3905–3908.
253. [253] Liu, H., Li, Z., Qiu, D., Gu, Q., Lei, Q., Mao, L., The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 485 (2010), 83–88.
254. [254] Kim, D.S., Park, S.Y., Kim, J.K., Curcuminoids from Curcuma Longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 303 (2001), 57–61.
255. [255] Park, S.Y., Kim, H.S., Cho, E.K., Kwon, B.Y., Phark, S., Hwang, K.W., et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol 46 (2008), 2881–2887.
256. [256] Ono, K., Hasegawa, K., Naiki, H., Yamada, M., Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75 (2004), 742–750.
257. [257] Marambaud, P., Zhao, H., Davies, P., Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280 (2005), 37377–37382.
258. [258] Feng, Y., Wang, X.P., Yang, S.G., Wang, Y.J., Zhang, X., Du, X.T., et al. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30 (2009), 986–995.
259. [259] Rivière, C., Papastamoulis, Y., Fortin, P.Y., Delchier, N., Andriamanarivo, S., Waffo-Teguo, P., et al. New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett 20 (2010), 3441–3443.
260. [260] Richard, T., Poupard, P., Nassra, M., Papastamoulis, Y., Iglésias, M.-L., Krisa, S., et al. Protective effect of ε-viniferin on β-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry. Bioorganic &. Med Chem 19 (2011), 3152–3155.
261. [261] Iuvone, T., De Filippis, D., Esposito, G., D'Amico, A., Izzo, A.A., The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J Pharmacol Exp Ther 317 (2006), 1143–1149.
262. [262] Pitt, J., Roth, W., Lacor, P., Smith, A.B. 3rd, Blankenship, M., Velasco, P., et al. Alzheimer's-associated abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 240 (2009), 189–197.
263. [263] Bazoti, F.N., Bergquist, J., Markides, K., Tsarbopoulos, A., Localization of the noncovalent binding site between amyloid-beta-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. J Am Soc Mass Spectrom 19 (2008), 1078–1085.
264. [264] Kostomoiri, M., Fragkouli, A., Sagnou, M., Skaltsounis, L.A., Pelecanou, M., Tsilibary, E.C., et al. Oleuropein, an anti-oxidant polyphenol constituent of olive promotes alpha-secretase cleavage of the amyloid precursor protein (AbetaPP). Cell Mol Neurobiol 33 (2013), 147–154.
265. [265] Rigacci, S., Guidotti, V., Bucciantini, M., Nichino, D., Relini, A., Berti, A., et al. Abeta(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr Alzheimer Res 8 (2011), 841–852.
266. [266] Wang, S.W., Wang, Y.J., Su, Y.J., Zhou, W.W., Yang, S.G., Zhang, R., et al. Rutin inhibits beta-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines. Neurotoxicology 33 (2012), 482–490.
267. [267] Yao, Z., Drieu, K., Papadopoulos, V., The ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 889 (2001), 181–190.
268. [268] Luo, Y., Smith, J.V., Paramasivam, V., Burdick, A., Curry, K.J., Buford, J.P., et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo Biloba extract EGb761. Proc Natl Acad Sci U S A 99 (2002), 12197–12202.
269. [269] Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 2008 (1780), 819–825.
270. [270] Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., Yamada, M., Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87 (2003), 172–181.
271. [271] Jhoo, J.H., Kim, H.-C., Nabeshima, T., Yamada, K., Shin, E.-J., Jhoo, W.-K., et al. β-amyloid (1–42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155 (2004), 185–196.
272. [272] Abbas, S., Wink, M., Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17 (2010), 902–909.
273. [273] Yang, F., Lim, G.P., Begum, A.N., Ubeda, O.J., Simmons, M.R., Ambegaokar, S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 (2005), 5892–5901.
274. [274] Frautschy, S.A., Hu, W., Kim, P., Miller, S.A., Chu, T., Harris-White, M.E., et al. Phenolic anti-inflammatory antioxidant reversal of abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22 (2001), 993–1005.
275. [275] Garcia-Alloza, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T., Bacskai, B.J., Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102 (2007), 1095–1104.
276. [276] Choi, S.J., Lee, J.H., Heo, H.J., Cho, H.Y., Kim, H.K., Kim, C.J., et al. Punica Granatum protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer's symptoms in mice. J Med Food 14 (2011), 695–701.
277. [277] Augustin, S., Rimbach, G., Augustin, K., Schliebs, R., Wolffram, S., Cermak, R., Effect of a short- and long-term treatment with ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys 481 (2009), 177–182.
278. [278] Jagota, S., Rajadas, J., Effect of phenolic compounds against abeta aggregation and abeta-induced toxicity in transgenic C. elegans. Neurochem Res 37 (2012), 40–48.
279. [279] Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Multifunction of myricetin on a beta: neuroprotection via a conformational change of a beta and reduction of a beta via the interference of secretases. J Neurosci Res 86 (2008), 368–377.
280. [280] Mori, T., Rezai-Zadeh, K., Koyama, N., Arendash, G.W., Yamaguchi, H., Kakuda, N., et al. Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 287 (2012), 6912–6927.
281. [281] Diomede, L., Rigacci, S., Romeo, M., Stefani, M., Salmona, M., Oleuropein aglycone protects transgenic C. elegans strains expressing Abeta42 by reducing plaque load and motor deficit. PLoS One, 8, 2013, e58893.
282. [282] Ringman, J.M., Younkin, S.G., Pratico, D., Seltzer, W., Cole, G.M., Geschwind, D.H., et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71 (2008), 85–92.
283. [283] Goedert, M., Spillantini, M.G., Tau gene mutations and neurodegeneration. Biochem Soc Symp, 59-71, 2001.
284. [284] Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83 (1986), 4913–4917.
285. [285] Iqbal, K., Grundke-Iqbal, I., Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12 (2008), 38–55.
286. [286] Thal, D.R., Holzer, M., Rub, U., Waldmann, G., Gunzel, S., Zedlick, D., et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 163 (2000), 98–110.
287. [287] Ho, L., Yemul, S., Wang, J., Pasinetti, G.M., Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J Alzheimers Dis 16 (2009), 433–439.
288. [288] Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280 (2005), 7614–7623.
289. [289] Yao, J., Gao, X., Sun, W., Yao, T., Shi, S., Ji, L., Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid. Biochemistry 52 (2013), 1893–1902.
290. [290] Daccache, A., Lion, C., Sibille, N., Gerard, M., Slomianny, C., Lippens, G., et al. Oleuropein and derivatives from olives as tau aggregation inhibitors. Neurochem Int 58 (2011), 700–707.
291. [291] Li, W., Sperry, J.B., Crowe, A., Trojanowski, J.Q., Smith, A.B. 3rd, Lee, V.M., Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem 110 (2009), 1339–1351.
292. [292] Sul, D., Kim, H.S., Lee, D., Joo, S.S., Hwang, K.W., Park, S.Y., Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci 84 (2009), 257–262.
293. [293] Villaflores, O.B., Chen, Y.J., Chen, C.P., Yeh, J.M., Wu, T.Y., Effects of curcumin and demethoxycurcumin on amyloid-beta precursor and tau proteins through the internal ribosome entry sites: a potential therapeutic for Alzheimer's disease. Taiwan J Obstet Gynecol 51 (2012), 554–564.
294. [294] Götz, J., Deters, N., Doldissen, A., Bokhari, L., Ke, Y., Wiesner, A., et al. A decade of tau transgenic animal models and beyond. Brain Pathol 17 (2007), 91–103.
295. [295] Santa-Maria, I., Diaz-Ruiz, C., Ksiezak-Reding, H., Chen, A., Ho, L., Wang, J., et al. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Neurobiol Aging 33 (2012), 2072–2081.
296. [296] Wang, J., Santa-Maria, I., Ho, L., Ksiezak-Reding, H., Ono, K., Teplow, D.B., et al. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. J Alzheimers Dis 22 (2010), 653–661.
297. [297] Gong, E.J., Park, H.R., Kim, M.E., Piao, S., Lee, E., Jo, D.G., et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3beta. Neurobiol Dis 44 (2011), 223–230.
298. [298] Götz, J., Tau and transgenic animal models. Brain Res Rev 35 (2001), 266–286.
299. [299] Stolerman, I.P., Encyclopedia of psychopharmacology: springer. 2010.
300. [300] Budhiraja, R., Elementary Pharmacology & Toxicology 4e: popular Prakashan. 2005.
301. [301] Feart, C., Samieri, C., Barberger, Gateau P., Diet and Alzheimer's disease: new evidence from epidemiological studies. New research on nutrition in the prevention of Alzheimer's disease, 2010.
302. [302] Maher, P., Akaishi, T., Abe, K., Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci U S A 103 (2006), 16568–16573.
303. [303] Serra-Majem, L., Roman, B., Estruch, R., Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev 64 (2006), S27–S47.
304. [304] Scarmeas, N., Stern, Y., Mayeux, R., Manly, J.J., Schupf, N., Luchsinger, J.A., Mediterranean diet and mild cognitive impairment. Arch Neurol 66 (2009), 216–225.
305. [305] Nurk, E., Refsum, H., Drevon, C.A., Tell, G.S., Nygaard, H.A., Engedal, K., et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 139 (2009), 120–127.
306. [306] Kesse-Guyot, E., Fezeu, L., Andreeva, V.A., Touvier, M., Scalbert, A., Hercberg, S., et al. Total and specific polyphenol intakes in midlife are associated with cognitive function measured 13 years later. J Nutr 142 (2012), 76–83.
307. [307] Gu, Y., Nieves, J.W., Stern, Y., Luchsinger, J.A., Scarmeas, N., Food combination and Alzheimer disease risk: a protective diet. Arch Neurol, 67, 2010, 699.
308. [308] Devore, E.E., Grodstein, F., van Rooij, F.J., Hofman, A., Stampfer, M.J., Witteman, J.C., et al. Dietary antioxidants and long-term risk of dementia. Arch Neurol 67 (2010), 819–825.
309. [309] Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya project 1. Am J Clin Nutr 83 (2006), 355–361.
310. [310] Ng, T.P., Feng, L., Niti, M., Kua, E.H., Yap, K.B., Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 88 (2008), 224–231.
311. [311] Pinder, R.M., Does wine prevent dementia. Int J Wine Res 1 (2009), 41–52.
312. [312] Sokolov, A.N., Pavlova, M.A., Klosterhalfen, S., Enck, P., Chocolate and the brain: neurobiological impact of cocoa flavanols on cognition and behavior. Neurosci Biobehav Rev, 2013.
313. [313] Ng, T.-P., Chiam, P.-C., Lee, T., Chua, H.-C., Lim, L., Kua, E.-H., Curry consumption and cognitive function in the elderly. Am J Epidemiol 164 (2006), 898–906.
314. [314] Berr, C., Portet, F., Carriere, I., Akbaraly, T.N., Feart, C., Gourlet, V., et al. Olive oil and cognition: results from the three-city study. Dement Geriatr Cogn Disord 28 (2009), 357–364.
315. [315] Commenges, D., Scotet, V., Renaud, S., Jacqmin-Gadda, H., Barberger-Gateau, P., Dartigues, J.F., Intake of flavonoids and risk of dementia. Eur J Epidemiol 16 (2000), 357–363.
316. [316] Farr, S.A., Price, T.O., Dominguez, L.J., Motisi, A., Saiano, F., Niehoff, M.L., et al. Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis 28 (2012), 81–92.
317. [317] Li, Q., Zhao, H.F., Zhang, Z.F., Liu, Z.G., Pei, X.R., Wang, J.B., et al. Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Neuroscience 163 (2009), 741–749.
318. [318] Pitozzi, V., Jacomelli, M., Zaid, M., Luceri, C., Bigagli, E., Lodovici, M., et al. Effects of dietary extra-virgin olive oil on behaviour and brain biochemical parameters in ageing rats. Br J Nutr 103 (2010), 1674–1683.
319. [319] Assuncao, M., Santos-Marques, M.J., Carvalho, F., Lukoyanov, N.V., Andrade, J.P., Chronic green tea consumption prevents age-related changes in rat hippocampal formation. Neurobiol Aging 32 (2011), 707–717.
320. [320] Haque, A.M., Hashimoto, M., Katakura, M., Tanabe, Y., Hara, Y., Shido, O., Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J Nutr 136 (2006), 1043–1047.
321. [321] Haque, A.M., Hashimoto, M., Katakura, M., Hara, Y., Shido, O., Green tea catechins prevent cognitive deficits caused by Abeta1-40 in rats. J Nutr Biochem 19 (2008), 619–626.
322. [322] Pu, F., Mishima, K., Irie, K., Motohashi, K., Tanaka, Y., Orito, K., et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci 104 (2007), 329–334.
323. [323] Stackman, R.W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J., Quinn, J.F., Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic ginkgo biloba treatment. Exp Neurol 184 (2003), 510–520.
324. [324] Joseph, J.A., Denisova, N.A., Arendash, G., Gordon, M., Diamond, D., Shukitt-Hale, B., et al. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 6 (2003), 153–162.
325. [325] van Praag, H., Lucero, M.J., Yeo, G.W., Stecker, K., Heivand, N., Zhao, C., et al. Plant-derived flavanol (−)epicatechin enhances angiogenesis and retention of spatial memory in mice. J Neurosci 27 (2007), 5869–5878.
326. [326] Currais, A., Prior, M., Dargusch, R., Armando, A., Ehren, J., Schubert, D., et al. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell 13 (2014), 379–390.
327. [327] Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, A.F., A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo Biloba for dementia. North American EGb study group. JAMA 278 (1997), 1327–1332.
328. [328] Akhondzadeh, S., Noroozian, M., Mohammadi, M., Ohadinia, S., Jamshidi, A.H., Khani, M., Salvia Officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 28 (2003), 53–59.
329. [329] Krikorian, R., Shidler, M.D., Nash, T.A., Kalt, W., Vinqvist-Tymchuk, M.R., Shukitt-Hale, B., et al. Blueberry supplementation improves memory in older adults. J Agric Food Chem 58 (2010), 3996–4000.
330. [330] Krikorian, R., Boespflug, E.L., Fleck, D.E., Stein, A.L., Wightman, J.D., Shidler, M.D., et al. Concord grape juice supplementation and neurocognitive function in human aging. J Agric Food Chem 60 (2012), 5736–5742.
331. [331] Scholey, A.B., French, S.J., Morris, P.J., Kennedy, D.O., Milne, A.L., Haskell, C.F., Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. J Psychopharmacol 24 (2010), 1505–1514.
332. [332] Field, D.T., Williams, C.M., Butler, L.T., Consumption of cocoa flavanols results in an acute improvement in visual and cognitive functions. Physiol Behav 103 (2011), 255–260.
333. [333] Pase, M.P., Scholey, A.B., Pipingas, A., Kras, M., Nolidin, K., Gibbs, A., et al. Cocoa polyphenols enhance positive mood states but not cognitive performance: a randomized, placebo-controlled trial. J Psychopharmacol 27 (2013), 451–458.
334. [334] Kennedy, D.O., Wightman, E.L., Reay, J.L., Lietz, G., Okello, E.J., Wilde, A., et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91 (2010), 1590–1597.
335. [335] Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., Arancio, O., Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol 88 (2014), 450–467.
336. [336] Götz, J., Streffer, J., David, D., Schild, A., Hoerndli, F., Pennanen, L., et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 9 (2004), 664–683.
337. [337] Mancuso, C., Siciliano, R., Barone, E., Preziosi, P., Natural substances and Alzheimer's disease: from preclinical studies to evidence based medicine. Biochim Biophys Acta 2012 (1822), 616–624.